Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: A quantitative analysis from the ADVANCE MPI trials

John J. Mahmarian, Leif E. Peterson, Jiaqiong Xu, Manuel D. Cerqueira, Ami E. Iskandrian, Timothy M. Bateman, Gregory S. Thomas, Faisal Nabi

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Background: Total and reversible left ventricular (LV) perfusion defect size (PDS) predict patient outcome. Limited data exist as to whether regadenoson induces similar perfusion abnormalities as observed with adenosine. We sought to determine whether regadenoson induces a similar LV PDS as seen with adenosine across varying patient populations.

Methods and Results: ADVANCE MPI were prospective, double-blind randomized trials comparing regadenoson to standard adenosine myocardial perfusion tomography (SPECT). Following an initial adenosine SPECT, patients were randomized to either regadenoson (N = 1284) or a second adenosine study (N = 660). SPECT quantification was performed blinded to randomization and image sequence. Propensity analysis was used to define comparability of regadenoson and adenosine perfusion results. Baseline clinical and SPECT results were similar in the two randomized groups. There was a close correlation between adenosine and regadenoson-induced total (r 2= 0.98, P < .001) and reversible (r 2= 0.92, P < .001) PDS. Serial differences in total (0.00 ± 3.51 vs −0.11 ± 3.46, P = .51) and reversible (0.15 ± 3.79 vs 0.07 ± 3.33, P = .65) PDS were also comparable in patients randomized to regadenoson vs adenosine, respectively, and irrespective of age, gender, diabetic status, body mass index, or prior cardiovascular history. By propensity analysis, regadenoson-induced total PDS was significantly larger than observed with adenosine.

Conclusion: This is the first study to show that regadenoson induces similar, if not larger, perfusion defects than those observed with adenosine across different patient populations and demonstrates the value of quantitative analysis for defining serial changes in SPECT perfusion results. Regadenoson should provide comparable diagnostic and prognostic SPECT information to that obtained with adenosine.

Original languageEnglish (US)
Pages (from-to)248-261
Number of pages14
JournalJournal of Nuclear Cardiology
Volume22
Issue number2
DOIs
StatePublished - Mar 10 2015

Keywords

  • A2A adenosine receptor agonists
  • myocardial perfusion imaging: SPECT
  • vasodilator stress

Fingerprint Dive into the research topics of 'Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: A quantitative analysis from the ADVANCE MPI trials'. Together they form a unique fingerprint.

Cite this